Previously collected plasma samples from patients with benign breast disease, in situ carcinoma, invasive carcinoma with no lymph node involvement (Inv/LN−), and invasive carcinoma with lymph node involvement (Inv/LN+) were evaluated by ELISA for CMV IgG, cmvIL-10, and human cIL-10, IL-6, and TNFα. This evidence concerns the gene IL6 and invasive carcinoma.